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Abstract 
Rheumatic heart disease (RHD) is a preventable non-communicable condition that 
disproportionately affects the world's poorest and most vulnerable. The World Heart Federation 
Roadmap for improved RHD control is a resource designed to help a variety of stakeholders raise the 
proﬁle of RHD nationally and globally, and provide a framework to guide and support the 
strengthening of national, regional and global RHD control efforts. The Roadmap identiﬁes the 
barriers that limit access to and uptake of proven interventions for the prevention and control of 
RHD. It also highlights a variety of established and promising solutions that may be used to 
overcome these barriers. As a general guide, the Roadmap is meant to serve as the foundation for 
the development of tailored plans of action to improve RHD control in speciﬁc contexts. 
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1. Introduction 
Rheumatic heart disease (RHD) is a preventable non-communicable condition that 
disproportionately affects the world’s poorest and most vulnerable. Globally, 32 million people 
suffer from the condition, which kills 275,000 people annually [1]. Driven by poverty, poor access to 
health services and other health system weaknesses, the majority of people with RHD live in low- 
and middle-income countries, with the remainder in vulnerable communities of wealthy countries 
[2].
 
 
 
In recent years, the need for concerted global action to control non-communicable diseases, 
including RHD and other cardiovascular diseases (CVD), has become a high priority on the global 
health agenda. This prioritisation is evident in the UN political declarations on the Prevention and 
Control of Non-Communicable Diseases (‘25 by 25’ target), the WHO Global NCD Action Plan, and 
the UN Sustainable Development Goals [3, 4].
 
 
 
With CVD as the leading cause of premature mortality worldwide, and more than 80% of deaths 
occurring in low- and middle-income countries, the World Heart Federation (WHF), as the world’s 
leading global CVD organization, launched its Roadmap Initiative in 2014 to guide and support those 
seeking to improve CVD control.  
 
The WHF Roadmaps are global implementation strategies designed to help governments, employers, 
non-governmental organizations (NGOs), health activists, academic and research institutions, health 
care providers and people who have been affected by CVD, take action to better prevent and control 
CVD [5, 6]. The Roadmaps synthesise existing evidence on the efﬁcacy, feasibility and cost-
effectiveness of various strategies. They also identify potential barriers (roadblocks) to their 
implementation, and propose potential solutions to bypass them.  
 
The WHF Roadmap for reducing morbidity and mortality through improved prevention and control 
of RHD complements existing roadmaps on tobacco control [7], raised blood pressure [8], and the 
use of secondary prevention for CVD [9], and follows the 2013 WHF position statement on the 
prevention and control of RHD [10].  
 
As part of its 2013 statement on RHD, the WHF endorsed the ambitious goal of achieving a 25% 
reduction in premature deaths from rheumatic fever (RF) and RHD among individuals aged <25 years 
by 2025 [10]. 
 
To achieve this, the WHF also deﬁned ﬁve targets:  
 Foster at least one prominent public ﬁgure as an ‘RHD champion’ in every country where RHD is 
endemic, 
 Ensure that 90% of countries with endemic RHD have integrated and comprehensive control 
programmes by 2025, 
 Ensure the availability of high-quality benzathine penicillin G for 90% of patients with RHD in 
90% of countries with a high burden of this disease, 
 Establish at least one hub of training, research, and advocacy for RF and RHD in each WHO-
deﬁned geographic region by 2025, 
 Test a group A β-haemolytic streptococcal vaccine in phase III clinical trials in RHD-endemic 
countries within 10 years [10]. 
 
The WHF RHD Roadmap will contribute to reaching these targets by acting as a resource to raise the 
proﬁle of RHD nationally and globally, and by providing a framework to guide and support the 
strengthening of national, regional and global RHD control efforts.  
 
The Roadmap’s content is derived from searches for relevant systematic and narrative reviews of 
existing evidence found in Medline and the Cochrane Library; a synthesis of relevant peer-reviewed 
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and grey literature published since 2012; and an iterative process of expert consultation involving 11 
Writing Committee and 12 Reviewing Committee members drawn from the global WHF membership 
network and key stakeholders in RHD control. 
 
Given the diverse settings in which RHD is endemic and the array of opportunities for intervention 
(even within individual countries), this Roadmap is best considered a generic framework for local 
adaptation and is intended to serve as a basis for developing region- or country-speciﬁc roadmaps.  
 
Developing and effectively implementing country-speciﬁc roadmaps will require a coalition of the 
following stakeholders: health professionals; government departments and agencies; in-country and 
regional health organizations; NGOs; and industry, patient and community groups to advocate for 
the inclusion of RHD in national NCD action plans and various other national planning instruments. 
 
The process also requires a range of local expertise that includes knowledge of medicine, cardiology, 
cultural and social contexts, prevention, health promotion, health systems, economics, and 
government priorities. Section 10 discusses this process further.  
 
 
2. What are RF and RHD? 
Rheumatic fever is an inﬂammatory disease involving the joints, skin, heart and brain, which 
develops following an untreated or partially treated group A β-haemolytic streptococcal (GAS) 
infection of the throat (streptococcal pharyngitis). Up to 30% of sore throats in children and young 
people are caused by GAS, and 0.3-3% of young people with an untreated GAS sore throat will 
develop RF [11, 12]. 
 
 
 
Personal susceptibility, the type of GAS strain and poor socio-economic conditions that facilitate 
bacterial transmission and exposure, particularly overcrowded housing, are key risk factors for RF 
(see Figure 1). In some regions, streptococcal skin infection has also been implicated in the disease 
process [13]. 
 
 
 
After recovery from the initial episode of RF, up to 60–65% of patients develop valvular heart 
disease [11, 14] and the risk of RF recurrence following GAS infection rises to 50% [15, 16]. Repeated 
GAS infections without appropriate treatment with benzathine penicillin G lead to RF recurrences 
and progressive valve damage – the deﬁning characteristic of RHD – which can, in turn, cause atrial 
ﬁbrillation, heart failure, stroke and endocarditis.  
 
A key determinant of disease progression is the number of times RF recurs in an individual [17]. As 
cardiac impairment worsens, disability increases and quality of life decreases. Surgery or cardiac 
catheterisation often become necessary, and patients who do not have access to such treatment 
ultimately die prematurely from RHD and its complications. In a large study conducted in 14 low- 
and middle-income countries, the median age of death was 28.7 years [18].  
 
 
Figure 1: The interplay of risk factors for rheumatic fever 
 
 
3. Changing burden of a preventable disease 
By the 1980s, RF and RHD had virtually disappeared from high-income regions of North America and 
Europe [19, 20]. However, the disease burden persists in low- and middle-income countries, home to 
79% of people living with RHD [2], and in some Indigenous populations of higher-income countries 
[21, 22].  
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According to the WHO Global Health Estimates, the overall burden of RHD has declined over the past 
decade, though progress has been uneven [23]. Figures 2 and 3 illustrate the total deaths and 
disability-adjusted life-years (DALYs) estimated for each WHO region during 2000 and 2012. DALYs 
are a summary measure of health that capture both premature mortality and morbidity among 
prevalent cases in a single statistic. Reﬂecting morbidity in measures of burden is important as many 
people living with RHD are disabled by its long-term complications, which include heart failure, atrial 
ﬁbrillation, stroke, infective endocarditis, and pregnancy-related complications.  
 
At the global level, the number of deaths and DALYs attributed to RHD have decreased by 0.75% and 
1.33%, respectively, since 2000. Progress was most notable in high-income countries and in middle-
income countries in Europe and Southeast Asia. However, the total number of deaths in Africa and 
the Eastern Mediterranean increased over this period.  
 
Burden of disease estimates have also been produced by the Global Burden of Disease (GBD) studies 
from the Institute for Health Metrics and Evaluation. The GBD 2013 study estimated 275,000 deaths 
globally (95% uncertainty interval [UI]: 222,600-353,900) for 2013 in comparison to the WHO 
estimate of 337,335 deaths [24]. The GBD 2013 study also estimated 32.9 million (31.6-34.0 million) 
prevalent cases and 9.5 million (7.9 million-12.0 million) DALYs from RHD in 2013 [1, 24]. Together, 
these ﬁndings suggest that the reductions in mortality may be resulting in an increased prevalence. 
 
 
Figure 2: Global deaths from RHD by WHO region, 2000-2012.  
Source: WHO Global Health Estimates (GHE) database. LMIC: low- and middle-income country 
 
 
Figure 3: Disability-adjusted life years due to RHD by WHO region, 2000-2012.  
Source: WHO Global Health Estimates (GHE) database. LMIC: low- and middle-income country 
 
 
4. Why control RF and RHD? 
There are a number of compelling reasons to act on RHD, in addition to the total global burden of 
disease [25]. As noted above, progress on RHD has been uneven, with some low-income areas 
experiencing increases in mortality as compared to high-income areas where mortality has 
decreased. Therefore, RHD contributes to rising health inequality at the global level.  
 
Unlike many other CVDs, RHD is a preventable condition acquired in childhood that is amenable to 
early and effective intervention. This presents a rare opportunity to avert the immense personal 
burden and social costs associated with premature cardiovascular morbidity and mortality [26]. The 
potential economic gains from a societal perspective are even greater, as the burden of RHD is 
disproportionately borne by young, economically active people in low-income countries [26, 27]. 
Therefore, controlling RHD supports overall economic and social development, both directly and 
indirectly. 
 
RHD acts as a tracer condition that reveals issues in the performance of health systems. 
Comprehensive RHD control spans the whole health system, requiring robust primary care systems 
all the way up to specialised tertiary and quaternary care. RHD control programmes also present an 
opportunity to model good practice in the delivery of services to those with chronic conditions that 
require ongoing management. If done well, the learning and experience can be transferred to 
beneﬁt other public health programmes.  
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Given the elevated risk associated with poverty and the impoverishing effects of the disease, 
addressing RHD is also an issue of equity in all affected countries, regardless of income level. It is 
also a matter of equity for women’s health, as pregnancy and labour are particularly dangerous for 
women with RHD [28].  
 
 
5. The health care journey in RHD 
Although local differences in health services can be profound, people with streptococcal pharyngitis 
(‘strep throat’), RF and RHD share a number of common health care needs. These common pathways 
are illustrated in Figure 4, which draws on the Continuum of Care (CoC) Framework for Health 
Systems developed by Medtronic Foundation.1 The framework acknowledges the interrelated nature 
of strep throat, acute RF and RHD, and traces a stylised version of the patient journey through the 
types (and level) of intervention required at each stage. These are numbered CoC1 to CoC10 in the 
Figure.  
 
For instance, an unwell individual or their caregiver must initially decide to seek care for the illness 
(CoC2), and then engage with the health system (CoC3) where they should be appropriately 
diagnosed (CoC4) either with strep throat (path 1), rheumatic fever (path 2) or rheumatic heart 
disease (path 3). Those with strep throat should receive appropriate treatment with intramuscular 
benzathine penicillin G (BPG), ideally at the primary care level (CoC6). Those diagnosed with 
rheumatic fever should begin secondary prophylaxis using BPG (CoC7) also at the primary care level, 
and be referred for appropriate investigation at higher levels. And those with RHD should be 
referred (CoC5) for appropriate treatment at higher levels of care (CoC8), after which they should 
receive the appropriate follow-up care (CoC9 and CoC10). The framework also underscores the roles 
that poverty and the social determinants of health play as crucial risk factors for RHD (CoC1).  
 
As a patient-centred framework, the CoC facilitates an understanding of the care seeking process 
from the individual’s – or their caregiver’s – perspective, while permitting the systematic 
identiﬁcation and categorisation of the various needs and opportunities of patients, providers, 
communities and the wider health system to manage cases of GAS sore throat, RF and RHD 
appropriately, and prevent the progression of disease. 
 
 
Figure 4: RF and RHD Continuum of Care 
 
 
6. Key interventions for treatment and prevention 
Underpinning the CoC are a number of evidence-based interventions to alter the outcome of 
disease. The WHF and RhEACH 2 have developed a matrix (Figure 5) to summarise these treatments 
and a wide range of supporting interventions into a resource called the Tools for Implementing RHD 
Control Programmes (TIPS) Handbook [29]. These are typically considered in four domains:  
 Primordial (address the underlying social determinants of health that exacerbate GAS exposure 
and RHD risk)  
 Primary (treatment of strep throat to prevent the development of RF following GAS infection)  
 Secondary (prevent development of new GAS infections following the ﬁrst episode of acute RF 
to prevent subsequent RF recurrences and delay or prevent development of severe RHD)  
 Tertiary (control RHD symptoms and extend the life of those living with RHD)  
                                                          
1 Medtronic Foundation and RhEACH are founding partners of RHD Action (www.rhdaction.org). Medtronic Foundation focuses on 
expanding access to quality chronic disease care among underserved populations worldwide. 
2 RhEACH (www.rheach.org) is a technical support and policy translation initiative that aims to amplify rheumatic heart disease control 
efforts worldwide, and provides clinical, technical and research support to the global RHD Action movement. 
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Figure 5: TIPS matrix of RHD control supporting interventions 
 
 
6.1. Primordial prevention 
As a disease with aetiology and risk factors strongly associated with poverty, structural interventions 
designed to address the social determinants of health are believed to be critical for RF and RHD 
control [30, 31]. These interventions aim to reduce exposure to GAS infection by addressing 
household overcrowding and other social determinants of health.  
 
While such interventions traditionally lie beyond the scope of health system strengthening, there 
may be scope for primordial activity, such as education on overcrowding, to be combined with other 
RHD control efforts [29]. In addition, a wide range of government policies outside the health sector 
may also inﬂuence the primordial determinants of RHD. Therefore, advocacy on the association 
between RHD and poverty will help to ensure that governments, development partners, non-
governmental organizations and other important actors view RHD control as a priority.  
 
 
6.2. Primary prevention 
Primary prevention involves prompt diagnosis and treatment of GAS throat infections in young 
people, with effective use of antibiotics to prevent the development of RF. This requires patients or 
their caregivers to seek care, receive appropriate diagnosis and adhere to prescribed treatment. A 
systematic review evaluating the effectiveness of antibiotics in preventing RF found a substantial 
protective effect: in patients with a sore throat and symptoms suggestive of a GAS infection, 
antibiotic treatment using intramuscular BPG could reduce the risk of RF by up to 80% [32]. A more 
recent review has endorsed penicillin as the antibiotic of choice for GAS pharyngitis [33].  
 
However, many roadblocks exist to the provision of effective primary prevention. From the patient’s 
perspective:  
 Since most sore throats are viral in nature and tend to be self-limiting, sore throat may not be 
considered an illness that warrants medical care, or its link with RF/RHD may be poorly 
understood, consequently affecting the uptake of effective care,  
 Access to preventive services and medication may be hindered by distance or costs, particularly 
if paid for out-of-pocket (e.g. transport, fees for diagnosis and medications) [30],  
 Poor adherence to antibiotic treatments may result from a lack of understanding of the purpose 
of treatment, and fear of injections, among other things.  
 
From the health systems perspective, the delivery of effective primary prevention may be hindered 
by:  
 Shortages and stock outs of essential antibiotics, including quality BPG, which may result from 
inefﬁcient procurement and supply chain management practices, or supply issues at the 
production/manufacturer level [34],  
 Poor understanding among health professionals about the purpose of treating sore throat and 
the link with RHD,  
 Insufﬁcient knowledge or systems at primary care level for the effective management of sore 
throat,  
 Absence of standardised clinical guidelines,  
 Inadequate training, resources or capacity to act on clinical guidelines which may be due to a 
lack of practical local clinical guidelines or, where they do exist, ineffective dissemination and 
uptake of guidelines among health professionals,  
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 Limited geographic coverage of existing primary healthcare services, 
 Reluctance to administer penicillin out of concern for anaphylaxis [35], resulting in onerous skin 
testing before administration in some settings and, in other settings, blanket bans on penicillin 
administration. 
 
While primary prevention is ideally delivered through the existing primary care system, alternative 
approaches, such as school-based sore throat clinics, have been suggested as a means of identifying 
GAS infections within the community and overcoming some of the aforementioned barriers to 
seeking care. While available evidence on the effectiveness of such programmes in preventing RF is 
limited [36], the recent experience of the sore throat management component of New Zealand’s RF 
primary prevention programme suggests that school-based approaches may be beneﬁcial when 
focused on areas of high RF incidence [37]. However, the high costs, workloads and logistical 
challenges associated with its delivery will likely limit its application in resource-constrained settings.  
 
Currently there is no effective vaccine for GAS (discussed further in Section 8).  
 
 
6.3. Secondary prevention  
The mainstay of secondary prevention involves the use of antibiotic prophylaxis in those with a 
history of RF to prevent subsequent recurrences, with the aim of limiting progression to severe RHD.  
 
The preferred antibiotic is intramuscular BPG, which must be administered every 28 days (shorter 
dose intervals may be used in some settings based on evidence about the duration of the protective 
effect of BPG, logistics of delivery and acceptability to patients), consistently for a minimum of 10 
years after the ﬁrst acute RF episode. Oral regimens provide inferior protection from RF recurrence, 
but may be required for people with a penicillin allergy [38-40].  
 
Effective delivery of secondary prevention requires identiﬁcation of all individuals at risk of RF 
recurrence, prompt initiation of antibiotic prophylaxis using BPG and on-going antibiotic delivery 
until the period of risk has passed. Consequently, adherence to secondary prophylaxis may be low. 
One study in Uganda noted that 46% of patients received less than 80% of the required injections 
over a 6-month period [41].  
 
Because secondary prophylaxis is similar to primary prevention in that it is ideally delivered through 
the primary care system and relies on BPG as the antibiotic of choice, many of the potential 
roadblocks are also similar. From the patient perspective:  
 RF may go undiagnosed because symptoms are mild or absent, or because families cannot afford 
to seek care,  
 The costs associated with the long duration of prophylaxis may be prohibitive, particularly if 
families must pay for BPG out-of-pocket [42]. The indirect costs of travel for injections may also 
be high, further increasing the risk for non-adherence, especially among patients or caregivers 
who do not value or understand the purpose of on-going follow up and treatment, or the 
beneﬁts of monitoring one’s disease status,  
 Poor adherence may also arise due to pain from regular injections,  
 Poor acceptability due to lack of trust or conﬁdence in the care provided or a perceived lack of 
patient/carer support may also affect adherence [42].   
 
From the health systems perspective:  
 Clinicians may not have the training or resources to diagnose RF accurately [43],  
 Lack of local guidelines, or their ineffective implementation can lead to inconsistent diagnosis, 
treatment and management of patients,  
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 Unreliable supply of quality antibiotics, especially BPG, and injection equipment is an important 
determinant of non-adherence [34, 44],  
 Concerns about anaphylaxis, particularly among asymptomatic children, may make some health 
professionals reluctant to administer BPG [35], and in some settings this has led to bans on 
penicillin administration,  
 Lack of primary care infrastructure to support delivery of secondary prevention.  
 
The core supporting intervention for the delivery of secondary prophylaxis is the national RF and 
RHD register, which has remained a critical part of RHD control since the 1970s. Registers beneﬁt 
those living with RF/RHD in various ways. They improve the delivery of consistent and standardised 
secondary prophylaxis, help to ensure that care is prioritised by need, and help to identify and 
support people with poor adherence. As a national information system, registers also contain 
important information about mortality, surgeries received and medical histories of individual 
patients, in addition to incidence and prevalence data and other important indicators over time [29, 
45].  
 
RHD may be asymptomatic for years or decades, particularly if the ﬁrst episode of RF was mild or 
undiagnosed. Identifying subclinical RHD cases through echocardiography screening has been 
advocated as a tool to support secondary prevention. In order to standardise the criteria used to 
diagnose subclinical RHD using echocardiography, a group of international experts under the 
auspices of the WHF has published evidence-based criteria for echocardiographic diagnosis of 
subclinical RHD in screening programmes [46].  
 
However, the priority of RHD control programmes should be to deliver effective secondary 
prophylaxis services before implementing echocardiographic screening programmes. The utility and 
cost-effectiveness of screening and treating subclinical cases should also be further investigated in 
more diverse settings [47].  
 
 
6.4. Tertiary intervention  
Tertiary RHD interventions aim to treat symptoms, reduce disability and ultimately delay death from 
RHD. Depending on the type and severity of a patient’s condition, tertiary interventions may include 
surgical valve repair, valve replacement, balloon mitral valvuloplasty or medical management of the 
complications of RHD.  
 
In the context of a developing country, it may be reasonable to include tertiary medical and surgical 
services within the remit of RHD control programmes where capacity and resources permit [45]. 
Valve repair has been shown to be preferable to replacement as patient survival is better and 
anticoagulation is not needed; however, repeat operations are often required [48, 49].  
 
Patients with valve replacements require lifelong anticoagulation using warfarin. This gives rise to a 
number of additional roadblocks in resource-limited settings as effective anticoagulation involves 
regular monitoring, regular dose adjustments and requires a reliable medicine supply.  
 
Making anticoagulation management available at primary care level has been suggested to improve 
access for these postoperative patients and for others requiring anticoagulation for arrhythmias and 
heart failure. Providing surgeries in these contexts may be prohibitively expensive for governments 
and patients alike [50].  
 
In many developing countries, cardiac surgery facilities do not exist; the small minority of patients 
who do receive tertiary care either travel overseas, or beneﬁt from international teams who visit on 
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short-term bases [51]. Several countries such as South Africa, India, and Brazil have increased 
capacity to deliver tertiary interventions [52]. Others in Africa have initiated surgical training 
programmes to address this gap, but this has not yet started to address the scale of the problem 
given that the vast majority of RHD cases in the region present with established disease and severe 
complications [53].  
 
While the ability to deliver tertiary interventions is important, where such capacity does not already 
exist, efforts should be made to invest in improving primary and secondary prevention, which are 
much more affordable and likely to reduce the future burden of disease, even if they cannot address 
the need for treatment [54].  
 
 
7. Key health system requirements for RHD control  
Examining the roadblocks at each level of intervention reveals several core health system features 
that are required for the effective implementation of RHD control programmes.  
 
 
7.1. Human resources  
A complementary range of clinical, allied health, public health and administrative skills that reﬂects 
the local burden of disease is required to implement RHD control programmes. However, experience 
from successfully implemented programmes has revealed the importance of a single key contact 
dedicated to developing and delivering the programme [29].  
 
Engaging existing networks of community health workers and nurses, who operate in rural and 
remote areas, presents an opportunity to greatly expand programme coverage and explore new 
delivery models for RHD control. In low- and middle-income countries, community health workers 
have been shown to be effective at delivering a variety of primary care interventions, including 
malaria case management [55], family planning services, and antenatal counselling and referral [56]. 
Their skill set and position within communities make them an ideal channel to administer RHD 
awareness campaigns and provide support to patients and carers.  
 
 
7.2. Healthcare delivery  
Many core components of RHD control programmes are well suited for a primary care approach, 
including delivery of primary and secondary prophylaxis, diagnosis of suspected RF and 
patient/community education. The renewed drive toward universal access to primary care provided 
by the Sustainable Development Goals presents a unique window of opportunity to achieve this 
integration [57].  
 
In addition to increasing service access for patients, the efﬁciencies gained from the sharing of 
infrastructure and resources also contributes to the sustainability of RHD control programmes. In 
Nepal, a national programme focused on promoting community awareness, the delivery of 
secondary prophylaxis, RHD register development, health worker training, and guideline 
development has been integrated into primary care since 2007; and in 2013 a pilot primary 
prevention project was initiated at 42 primary health centres [35].  
 
The devastating consequences of RHD during pregnancy and labour also require RHD control to be 
integrated with maternal care. Ensuring adequate counselling for women of childbearing age living 
with RHD, adequate antenatal case detection services and appropriate care during the perinatal 
period are essential components of a comprehensive RHD program. There are also recent initiatives 
that seek to integrate RHD care into other existing chronic disease management programmes. One 
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innovative approach being trialled in Uganda aims to integrate RHD surveillance and treatment 
within the existing HIV/AIDS infrastructure that has been successfully scaled-up after many years of 
domestic and foreign investment [58].  
 
 
7.3. Physical resources  
A continuous supply of affordable, quality intramuscular BPG for use as primary and secondary 
prophylaxis is a critical input for successful RHD control programmes. Invented in 1928, this 
antibiotic has been included on the WHO Essential Medicines List since the ﬁrst edition was 
published in 1977. However, several important concerns remain about BPG shortages at production 
level, efﬁcacy and quality, and persistent stock outs which continue to limit access [34].  
 
To improve availability of BPG and other essential medicines required for control programmes, they 
must be registered with the national pharmaceutical regulator and included on national 
formularies/essential medicines lists. RHD control programmes must also have sufﬁcient capacity to 
forecast, quantify, procure and distribute medicine supplies.  
 
Because BPG is also used to prevent transmission of syphilis in pregnant women to the foetus, and 
as prophylaxis in children with sickle cell disease, information ﬂow is critical to inform each of these 
processes and to minimise the risk of stock outs.  
 
For example, in Fiji, BPG usage data collected through the Rheumatic Fever Information System are 
used by the Fiji Pharmaceutical Biomedical Services to help ensure a more consistent supply of BPG 
to health facilities across the country. Where there is insufﬁcient capacity in procurement and supply 
chain management, support is available from alternative procurement agents including UN agencies, 
and a range of international and non-governmental organizations [59].  
 
 
7.4. Clinical resources  
Clear, practical, evidence-based clinical guidelines must be developed for each intervention provided 
and adapted to the particular context. To ensure they are used to inform the care provided, 
guidelines must be widely available at primary care level, translated into local languages as needed, 
and health care providers must be aware and trained on how to use them.  
 
To embed them further into clinical practice, guidelines may be integrated into medical education 
and the process of professional audit. Guidelines for RHD control should also include advice on how 
to educate patients about the risks of sore throat, RF and RHD; how to support patient adherence to 
secondary prophylaxis; and how to administer BPG injections safely, comfortably and conﬁdently.  
 
 
7.5. Governance and advocacy  
Embedding RHD control programmes within the Ministry of Health and other public health 
infrastructure is crucial for ensuring continued leadership, finance and, consequently, a sustainable 
and coordinated national response. However, successful experiences from Nepal and Sudan have 
shown that collaborations between government and NGOs, such as national heart foundations and 
professional societies, also provide effective models for programme governance [35, 60].  
 
Where government support and recognition of the need for RF/RHD control is lacking, advocacy 
must be used to mobilise political will and raise RHD control as a priority. A key advocacy ﬁgure at 
country level is the national or even regional ‘RHD Champion’ to whom the WHF targets refer in 
Section 1. RHD Advisory Committees, comprised of a broad and inclusive range of stakeholders, are 
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another important channel for conducting such advocacy, and can also play a role in the design, 
implementation and oversight of control programmes.  
 
 
7.6. Financing  
Programmes require sustained long-term funding to realise population-level impact, and therefore 
rely on strong advocacy and a good understanding of programme costs. In resource-constrained 
settings, public sources should ﬁnance primary and secondary prevention, as they are cost-effective 
and represent good value for money [12, 61-64]. Public ﬁnancing for prevention should aim to 
deliver care that is free at the point of service or that poses minimal cost to patients.  
 
Financing tertiary care and making it affordable to patients in these settings, if included, presents a 
great challenge given the socio-economic position of those most affected and the high costs of 
building and maintaining the required capacity and infrastructure. Where these resources do not 
exist, tertiary care could initially be ﬁnanced and delivered through alternative models [51]; and 
where there are shortfalls in public ﬁnancing, additional funds may be available from various 
external sources such as international donor agencies, professional organizations and charities [29]. 
However, ensuring equitable and affordable access to tertiary care requires effective ﬁnancial 
protection, such as that provided by comprehensive insurance and universal health coverage.  
 
Ultimately, the goal of RHD control is to reduce the incidence of acute RF and the prevalence of RHD, 
which, over time, will decrease the need for costly tertiary interventions.  
 
 
7.7. Information systems  
As discussed in Section 6, national RF and RHD registers are essential to support the delivery of 
secondary prophylaxis, and are important information systems that provide data to assess disease 
burden, target interventions according to need, and evaluate programme impact over time. 
Recently, an open-source, low-cost software application, called eRegister, has been developed by 
the Pan-African Society of Cardiology for RHD treatment and prevention programmes [65]. Based on 
the WHF framework for RHD patient registers, the software ensures the capture of standardised 
data, facilitating the production of indicators for programme monitoring and evaluation. It is also 
designed as a readily adaptable, cloud-based, mobile platform that allows for simultaneous data 
collection by ﬁeld workers using mobile devices, and by providers using computer terminals in clinics 
and hospitals.  
 
 
7.8. Patients and caregivers  
Ensuring patients, parents, schoolteachers, carers and communities are aware of the risks posed by 
untreated sore throat, RF and RHD through campaigns has been a core element of many successful 
RHD control programmes [35, 66, 67]. Raising awareness aims to increase the likelihood of seeking 
prompt care for sore throat, or when one shows signs and symptoms consistent with acute RF.  
 
Successful community-level campaigns have taken a multichannel approach, targeting several areas, 
as well as mass media, to reach as many people as possible. School and educational institutions 
should also be targeted, as the most vulnerable population for GAS infections are school-aged 
children [68]. In Kenya, the use of an interactive digital module to train school-going children on RHD 
was shown to increase knowledge and awareness [69].  
 
 
8. Opportunities to bridge the knowledge-practice gap  
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While the efﬁcacy of the clinical interventions and elements required for successful implementation 
of RHD control programmes are relatively well understood, the continuing global burden of this 
preventable disease highlights the ongoing knowledge-practice gap in RHD control. There are a 
number of important unanswered questions (Table 1), which will require robust research in order to 
produce the high-quality evidence needed to inﬂuence public health policy and programmes.  
 
 
Table 1: Unanswered questions related to the knowledge practice gap in RHD control (adapted from 
[52]) 
 What factors determine effective integration of RHD control activities into primary care or 
other existing programmes (e.g. chronic disease, perinatal or sexual health services)?  
 What programme characteristics contribute to improved delivery, uptake and adherence to 
secondary prophylaxis?  
 How can the supply and demand for BPG be better linked, or a more acceptable product be 
developed to control RHD?  
 How can successful experiences of implementing and scaling up comprehensive RHD control 
programmes be replicated? And what are the key factors that contributed to their success?  
 What is the relative cost-effectiveness of different approaches to RHD control, including 
different models for delivering primary prophylaxis and comprehensive RHD control 
programmes?  
 What is the clinical impact and cost-effectiveness of echocardiographic screening and other 
early case detection strategies, and how can it be made more practical and affordable?  
 What are the best approaches for increasing the availability and quality of epidemiological 
data on RHD disease burden, particularly in low- and middle-income countries?  
 How can people living with RHD be best empowered to improve self-management and 
outcomes? 
 
 
Innovative approaches that address roadblocks to effective care will also be required to close the 
knowledge-practice gap in RHD control. The remainder of this section explores a selection of these 
potential solutions, some of which address RHD and others which draw inspiration from innovative 
solutions used to address other conditions. Note that many of the innovative approaches described 
below require further research, development and evidence from trials before they can be adopted 
and scaled-up for RHD control. Such points could inform the long-term RHD research agenda. Other 
ideas, however, could be pursued immediately.  
 
 
8.1. Diagnosis of sore throat  
Although throat cultures remain the gold standard for the diagnosis of GAS pharyngitis, the 
availability of rapid point-of-care antigen detection tests and clinical decision rules have created 
opportunities for new diagnostic approaches [70]. However, evaluations of available rapid tests have 
found considerable variation in their speciﬁcity and sensitivity [70-73], and the tests have not been 
validated in all endemic regions, so product selection must be carefully considered. The current cost 
of rapid tests is also likely to limit their use in resource-constrained settings [70]. Alternatively, a 
meta-analysis evaluating seven clinical decision rules suggested that the Joachim protocol could 
potentially be used either alone or in combination with a rapid test to guide treatment decisions in 
some settings [74].  
 
 
8.2. RHD diagnosis and screening  
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As described in Section 6, the application of echocardiography for identifying subclinical RHD cases is 
currently under investigation. However, the introduction of new devices and the decreasing cost of 
equipment have increased the potential to apply this approach more widely in developing countries 
for RHD diagnosis and screening. For example, one recent study in Uganda, which evaluated the use 
of a relatively affordable handheld ultrasound device against standard portable echocardiography 
for diagnosis, found it to be highly sensitive (90.2%) and speciﬁc (92.9%) in distinguishing between 
normal patients and those with RHD, when images were blindly reviewed according to the 2012 
WHF guidelines [75].  
 
The use of portable echocardiograms by trained nurses for screening has also recently been studied 
in Fiji [76, 77]. Following brief focused training, participating nurses in one study were able to obtain 
adequate-quality images and make reliable assessments on the presence and extent of valvular 
regurgitation in more than 2000 children [77]. While further research is required, these early studies 
do show some promise for models that include task shifting as a means of introducing population-
level screening in high-prevalence, resource-poor settings. 
 
 
8.3. Acceptability of BPG  
The success of primary and secondary prophylaxis would beneﬁt from improved acceptability of 
BPG. In practice, this requires a regular supply of a high-quality product that can be readily 
administered with minimal pain. The development of longer-acting BPG formulations would support 
adherence by reducing the frequency of injections and the ﬁnancial burden of administering 
prophylaxis for both patients and programmes [52]. In the interim, an innovative low-cost device 
that uses vibration to reduce discomfort from BPG injections has been trialled in New Zealand. 
When used with a local anaesthetic, the device reduced the pain and fear reported by children [78].  
 
Incentive-based interventions have been used to improve medication adherence for conditions such 
as drug or alcohol dependence, HIV and tuberculosis. A review found that such incentives increased 
adherence by a mean of 20 percentage points, but that effects varied widely [79]. Incentive-based 
interventions have been frequently used to inﬂuence health-seeking behaviour in low- and middle-
income countries (e.g. to encourage antenatal care and immunisations), and there is potential for 
secondary prophylaxis to beneﬁt from such schemes.  
 
 
8.4. mHealth solutions  
The use of mobile devices to support the delivery of medical care or public health services is 
collectively termed mHealth. Despite being a relatively new area of intervention, there have been 
many pilot studies of a wide range of applications. While there continues to be some debate about 
the evidence base supporting the scale-up of mHealth [80], there are a few applications that have 
the potential to beneﬁt RHD control. Applications have been developed to support adherence to 
antiretroviral and tuberculosis treatment, many of which have been designed for use and trialled in 
developing country settings [81, 82].  
 
The SMS for Life application is a text message-based platform for reporting stock levels of 
artemether-lumefantrine (AL), the ﬁrst line treatment for uncomplicated malaria, and also of rapid 
diagnostic tests (RDTs) for malaria at peripheral facilities. In one pilot study conducted among 
selected public facilities in Kenya, weekly stock counts of AL packs and RDTs were sent via a 
structured incentivised SMS communication process from health workers’ personal mobile phones 
to a web-based system accessed by district managers. At the end of the pilot period, stock-outs of AL 
were eliminated and RDT stock-outs declined by 24 percentage-points. The platform has since been 
scaled up in Tanzania to include over 5,000 public health facilities across the country [83, 84].  
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8.5. Patient and community empowerment  
Strategies that seek to engage and empower people living with RHD and their carers have the 
potential to greatly enhance the RHD response. A diverse array of approaches has been developed, 
largely as part of the response to HIV/AIDS [85] and increasingly for non-communicable diseases, 
which target different levels of individual involvement. At one end of the spectrum, interventions 
such as healthy living training for patients, one-to-one counselling and patient support groups aim to 
increase knowledge about the disease, inﬂuence treatment-seeking behaviour and improve overall 
quality of life. For example, some programmes have adopted the use of patient-held records and 
RHD calendars that act as treatment reminders, while providing health information messages [52].  
 
Approaches at the other end of the spectrum aim to empower affected individuals to be more active 
advocates and champions of a wider response. In Kenya, patients are being enabled to provide each 
other with health education and peer support [86]. In Fiji, a young RHD patient-advocate currently 
sits as a permanent member on the national RHD technical advisory committee, which provides 
high-level technical advice to the Ministry of Health. RHD patients and their carers in Fiji are also 
represented on a national working group formed speciﬁcally to better understand and address poor 
patient adherence rates [87].  
 
 
8.6. Access to tertiary interventions  
With growing capacity for cardiac surgery in a number of low- and middle-income countries, there is 
scope to implement bilateral or regional programmes that allow RHD patients living in countries with 
insufﬁcient capacity to access tertiary interventions abroad [52]. Such a reciprocal agreement has 
existed between Malta and the United Kingdom since 1975 [88]. Under the agreement, nearly 300 
Maltese nationals are referred annually for specialist care in ophthalmology, cardiac surgery, 
oncology and neurology, with one third of these patients being children.  
 
 
8.7. GAS vaccine  
The search for a GAS vaccine began in the 1950s yet, despite early human trials, no effective product 
for clinical use is available. Vaccine development faces several challenges, including limited 
commercial viability, the regional variability of GAS strains and a theoretical risk of stimulating an 
autoimmune response [70, 89].  
 
However, research has progressed and several vaccine candidates against GAS infection are 
currently in various stages of pre-clinical and clinical development. These include M protein-based 
vaccines (N-terminal vaccine candidates and M protein conserved region vaccines), and non-M 
protein vaccine candidates representing conserved GAS antigens [90, 91].  
 
In addition to preventing sore throat and RF, a GAS vaccine could potentially provide protection 
against skin infection/impetigo and severe invasive GAS disease including pneumonia, bacteraemia, 
necrotising fasciitis and streptococcal toxic shock syndrome. Unlike RF/RHD, these invasive diseases 
cause signiﬁcant morbidity and mortality in high-income settings; a GAS vaccine relevant to both 
high- and low-resource settings may provide a compelling economic opportunity [89].  
 
This market segmentation approach and the feasibility of developing a viable product has recently 
garnered the attention of the WHO Product Development for Vaccines Advisory Committee [92]. 
Once available, a product development partnership model may help to accelerate progress towards 
the registration of an effective GAS vaccine. Since the 1990s, a number of these international public-
16 
private collaborations have introduced a plethora of new medications, vaccines and diagnostics to 
beneﬁt populations in low- and middle-income settings [93-95].  
 
 
9. Roadmap to address existing roadblocks  
Overcoming the barriers – whether individual, community or system-related – that prevent 
individuals from receiving care for sore throat, RF and RHD are crucial to achieving optimal 
population-level RHD control. While the roadblocks obstructing this journey will vary by setting, 
Table 2 charts a map of potential solutions that may be used to overcome them. 
 
Table 2: Potential solutions to address barriers to improved RHD control 
Level of 
intervention 
Roadblock Potential solutions 
Primary 
prevention 
Prompt medical 
care is not sought 
for sore throat in 
children and 
young people 
• Targeted school- and community-level education and awareness 
campaigns 
Poor adherence 
to antibiotics 
• Targeted school- and community-level education and awareness 
campaigns 
• Ensure affordable and easy access to effective treatment 
• Provide single dose of injectable BPG rather than longer course of 
oral antibiotics 
• Support and enable health care professionals to deliver BPG 
injections confidently and safely 
• Reformulate BPG to make injections more acceptable to patients 
and providers 
Inappropriate 
management of 
sore throat in 
primary or 
community care 
services 
• Ensure practical, evidence-based local guidelines are available and 
accessible 
• Provide professional training on use of guidelines 
• Integrate guidelines into clinical education and professional audit 
• Consider use of point-of-care diagnostics and clinical decision rules 
to improve diagnosis 
Reluctance to 
administer BPG 
due to concerns 
for anaphylaxis 
• Ensure guidelines include safe administration techniques 
• Deliver training to providers on the risk of anaphylaxis and safe 
administration techniques 
• Ensure emergency kits and epinephrine (adrenaline) syringes are 
available 
Secondary 
prevention 
RF cases are not 
identified 
• Ensure primary care staff are sufficiently trained to identify 
suspected RF cases 
• Ensure robust protocols exist for referring suspected cases for 
definitive diagnosis 
• Support access to essential technologies including simple blood 
tests and echocardiography 
No register-based 
programme 
• Advocate for public investment in register infrastructure, including 
the implementation of electronic register platforms (eRegister) 
• Seek external sources of funding and technical support 
Cases do not 
enrol or are not 
promptly enrolled 
into a register-
based 
programme 
• Targeted school- and community-level education and awareness 
campaigns about the value of secondary prevention 
• Increase health workers’ awareness and appreciation of register-
based system 
17 
Enrolled cases are 
poorly managed 
• Ensure practical, evidence-based, local treatment guidelines are 
available to support delivery of standardised care 
• Provide professional training on use of guidelines 
• Integrate guidelines into clinical education and professional audit 
• Implement electronic register platform (eRegister) to support 
follow-up and patient review 
Reluctance to 
administer BPG 
due to concerns 
for anaphylaxis 
• Ensure guidelines include safe administration techniques 
• Provide training for providers on safe administration techniques 
• Ensure emergency kits and epinephrine (adrenaline) syringes are 
available 
Poor adherence 
to long term 
prophylaxis 
• Train staff to administer secondary prophylaxis confidently and 
safely with minimal pain 
• Ensure guidelines include advice on how to support patient 
adherence 
• Include reminder and recall systems in register-based programmes 
• Introduce outreach services to follow up non-adherent patients 
• Consider decentralised dispensing and mobile injection delivery 
where feasible 
• Consider mHealth reminder and incentive-based solutions 
• Implement empowerment strategies, including patient/carer 
support groups and awareness sessions 
• Reformulate BPG to make injections more acceptable to patients 
and providers 
Tertiary 
prevention 
Poor access to 
surgical 
interventions 
• Develop bilateral or regional programmes to provide cross-border 
care 
• Develop regional centres of excellence for cardiac surgery in 
appropriate countries 
Health 
systems 
RHD control is not 
prioritised 
• Conduct advocacy for RHD control 
• Gather data on local burden of disease, its economic impact and 
the benefits of investing in RHD control 
• Identify national RHD champions 
• Mobilise RHD Advisory Committee 
• Ensure RHD control is embedded within government 
ministry/department of health 
Insufficient funds • Conduct RHD control advocacy to mobilise funding from 
government and other sources 
• Generate cost savings by integrating RHD control into existing 
primary care and other programmes 
• Generate cost savings by employing efficient medicines 
procurement strategies 
Poor availability 
of BPG and other 
essential 
medicines for 
RHD control 
• Ensure all required medications are registered with national 
regulator and included on national formulary/essential medicines 
list 
• Train programme staff on effective forecasting, quantification, 
procurement and distribution 
• Strengthen information systems used to manage procurement and 
distribution of medicines 
• Consider mHealth solutions to reduce risk of stock outs 
• Advocate for BPG production solutions at a global level 
Limited coverage 
of current RHD 
control 
programmes 
• Integrate RHD control into existing primary care and other 
programmes 
• Provide training on RHD prevention and control to primary health 
care workers 
Preventive 
services are 
unaffordable 
• Targeted campaigns to increase awareness of where to obtain 
affordable/public preventive care 
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Poor access to 
diagnostics in 
peripheral 
settings 
• Ensure availability of essential laboratory services and 
echocardiography in selected sites 
• Consider implementing anticoagulation management in primary 
care, where feasible 
• Document the utility of rapid point-of-care diagnostics for GAS 
infection to help build the market case for these devices 
 
 
10. Adapting to develop regional and national RHD roadmaps  
The examples of successful, cost-effective and comprehensive RF/RHD control programmes 
implemented in resource-constrained settings demonstrate the great potential for impact in other 
settings with high RHD burdens [35, 63, 66, 67].  
 
As discussed above, the RHD and other WHF Roadmaps describe only general principles that must 
be adapted to produce region- or country-speciﬁc roadmaps. The WHF has described this process in 
a companion article [96], but it generally involves:  
 Developing and convening a multi-sectoral coalition to undertake the adaptation,  
 Conducting a situation analysis to characterise the epidemiologic proﬁle, the healthcare system 
and policy environment,  
 Conducting policy dialogues to identify and discuss speciﬁc barriers and potential strategies that 
are appropriate to the given context,  
 Developing a plan of action and a process to evaluate the implementation of the selected 
strategies.  
 
The process requires a broad range of stakeholders (e.g. public health specialists, health care 
professionals, government organizations, regional health organizations, industry, advocacy and 
patient groups) and a broad range of expertise (e.g. knowledge of medicine, cardiology, prevention, 
health promotion, health systems, economics, governmental priorities, and cultural and social 
contexts).  
 
To support this general process, a set of tools has been developed to adapt the WHF RHD Roadmap 
to speciﬁc national contexts. RhEACH has prepared a detailed Needs Assessment Tool to conduct the 
situation analysis and to develop, implement, monitor and evaluate adapted roadmaps.  
 
In parallel, the WHF is developing additional guidance for convening multi-sectoral coalitions and 
conducting policy dialogues at national level. RHD country and global scorecards will also be 
developed to facilitate progress monitoring, international comparisons and evaluation of attaining 
targets.  
 
Over time, country and regional experiences will be reported back and integrated with other 
emerging evidence to inform the updating and revision of the WHF Roadmaps.  
 
 
11. Conclusion  
Effective interventions to prevent the devastating consequences of RHD have existed for many 
decades. Yet, many people die prematurely each year due to RHD related complications, most of 
whom are from low- and middle-income countries or from poor and vulnerable groups in countries 
where the disease has, otherwise, disappeared.  
 
The WHF Roadmap for improved RHD control identiﬁes the various barriers that limit access to and 
uptake of these proven interventions. It also highlights a variety of proven and promising solutions 
that could be used to overcome these ‘roadblocks’. As a general guide, this Roadmap is meant to 
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serve as the foundation for the development of tailored plans of action to improve RHD control in 
speciﬁc contexts.  
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